论文部分内容阅读
目的探析高血压患者用厄贝沙坦、硝苯地平控释片联合治疗对其病情临床干预效果。方法此次研究对象资料主要选取于2014年-2016年本院收治高血压患者500例,设其中250例接受常规高血压干预措施控制患者为对照组,另250例联合厄贝沙坦、硝苯地平控释片治疗患者为观察组。结果对患者疗效进行评估,观察组有12例评估判定为无效,对照组患者有62例评估判定为无效,两组治疗总有效率经统计学处理对比提示有意义(P<0.05);记录患者治疗前后各项临床指标如舒张压、收缩压变化,干预后患者均有改善,观察组改善程度更突出(P<0.05);两组患者均无发生药物相关严重不良反应,顺利完成疗程。结论对高血压患者除了常规治疗方案外,和厄贝沙坦、硝苯地平控释片等相联合能够更好保障临床疗效,改善血压指标情况,对患者身体健康有重要意义,值得推广。
Objective To investigate the clinical effect of irbesartan and nifedipine controlled release tablets in patients with hypertension. Methods The data of this study were mainly selected from 500 cases of patients with hypertension in our hospital from 2014 to 2016. Among them, 250 cases were controlled by conventional hypertension intervention and the other 250 cases were combined with irbesartan and nifedipine Controlled-release tablets for the treatment of patients in the observation group. The results of the evaluation of the efficacy of the patients, the observation group of 12 cases judged to be invalid, the control group of 62 patients judged to be invalid, the total effective rate of the two groups treated by statistical analysis suggested significant (P <0.05); recorded patients Before and after treatment of various clinical indicators such as diastolic blood pressure, systolic blood pressure changes, the intervention patients were improved, the observation group improved more prominent (P <0.05); no serious drug-related adverse reactions in both groups, the successful completion of the course of treatment. Conclusion In addition to conventional treatment of hypertension patients, and irbesartan, nifedipine and other controlled release tablets to better protect the clinical efficacy and improve blood pressure indicators, the patient’s health is of great significance, it is worth promoting.